Related Experiment Video
Updated: Jan 15, 2026

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases
Published on: October 10, 2020
Novel Substituted Aryl Sulfonamides and Sulfuric Diamides As Transglutaminase 2 Inhibitors
Jian Rong1,2, Steven H Liang2,3
1Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology no. 1277 Jiefang Avenue, Wuhan, Hubei 430022, China.
Abstract:
This patent describes novel substituted aryl sulfonamides and sulfuric diamides as potent transglutaminase 2 (TG2) inhibitors. It provides details on the novel substituted aryl sulfonamide and sulfuric diamide compounds, pharmaceutical formulations, and the use of such compounds in the treatment of TG2-related diseases, such as fibrosis, neurodegenerative diseases, autoimmune diseases, and cancers.
Related Concept Videos
Oral Hypoglycemic Agents: Sulfonylureas
Dipeptidyl Peptidase 4 Inhibitors
Amines to Sulfonamides: The Hinsberg Test
Generally, a primary amine reacts with the Hinsberg reagent to produce an N-substituted benzenesulfonamide. The electron-withdrawing sulfonyl...
Phase II Reactions: Sulfation and Conjugation with α-Amino Acids
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Phase II Reactions: Glucuronidation

